{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:02:01Z","timestamp":1788519721937,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170806"],"award-info":[{"award-number":["82170806"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.labinv.2023.100210","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T20:59:09Z","timestamp":1688417949000},"page":"100210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma\/Paraganglioma"],"prefix":"10.1016","volume":"103","author":[{"given":"Anze","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4057","authenticated-orcid":false,"given":"Longfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.labinv.2023.100210_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.labinv.2023.100210_bib2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/cancers11081070","article-title":"Pheochromocytomas and paragangliomas: new developments with regard to classification, genetics, and cell of origin","volume":"11","author":"Koopman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2023.100210_bib3","doi-asserted-by":"crossref","first-page":"bvac105","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.labinv.2023.100210_bib4","article-title":"Pheochromocytoma and paraganglioma: a review of diagnosis, management and treatment of rare causes of hypertension","volume":"12","author":"Cerqueira","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.labinv.2023.100210_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.labinv.2023.100210_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/cancers11020225","article-title":"The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas. A meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2023.100210_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.labinv.2023.100210_bib8","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.3390\/cancers13163942","article-title":"Identification of immune cell infiltration in murine pheochromocytoma during combined mannan-BAM, TLR ligand, and anti-CD40 antibody-based immunotherapy","volume":"13","author":"Uher","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2023.100210_bib9","first-page":"88","article-title":"Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks","volume":"10","author":"Fanciulli","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.labinv.2023.100210_bib10","first-page":"76","article-title":"Cancer immunotherapy: an updated overview of current strategies and therapeutic agents","volume":"1","author":"Abu-Shawer","year":"2019","journal-title":"Gulf J Oncolog"},{"key":"10.1016\/j.labinv.2023.100210_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.labinv.2023.100210_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.labinv.2023.100210_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T\u00a0cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.labinv.2023.100210_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/med.21727","article-title":"Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy","volume":"41","author":"Hossain","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.labinv.2023.100210_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jcyt.2020.01.010","article-title":"Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome","volume":"22","author":"de Lima","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.labinv.2023.100210_bib16","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2023.100210_bib17","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.labinv.2023.100210_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/cancers14030467","article-title":"Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: Do they work?","volume":"14","author":"Jimenez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2023.100210_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fgene.2020.00015","article-title":"A\u00a0comprehensive analysis identified the key differentially expressed circular ribonucleic acids and methylation-related function in pheochromocytomas and paragangliomas","volume":"11","author":"Yu","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.labinv.2023.100210_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1358332","article-title":"Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior","volume":"6","author":"Pinato","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.labinv.2023.100210_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.humpath.2018.10.041","article-title":"PD-L1 expression and association with malignant behavior in pheochromocytomas\/paragangliomas","volume":"86","author":"Guo","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.labinv.2023.100210_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/cclm-2020-0904","article-title":"Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma","volume":"59","author":"Eisenhofer","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.labinv.2023.100210_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00345-014-1397-z","article-title":"Ten year experience of retroperitoneal laparoscopic resection for pheochromocytomas: a dual-centre study of 72 cases","volume":"33","author":"de Fourmestraux","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.labinv.2023.100210_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urology.2016.09.004","article-title":"Surgical and hemodynamic outcomes in pheochromocytoma surgery: A prospective cohort study","volume":"98","author":"Rao","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.labinv.2023.100210_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12957-019-1649-x","article-title":"Comparison of retroperitoneal laparoscopic versus open adrenalectomy for large pheochromocytoma: a single-center retrospective study","volume":"17","author":"Zhu","year":"2019","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.labinv.2023.100210_bib26","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.labinv.2023.100210_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cca.2010.01.012","article-title":"Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma","volume":"411","author":"Peaston","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.labinv.2023.100210_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.labinv.2023.100210_bib29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: new insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.labinv.2023.100210_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.2014.980235","article-title":"The PD-1\/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy","volume":"19","author":"Muenst","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.labinv.2023.100210_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.labinv.2023.100210_bib32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13256-021-02733-5","article-title":"The use of immunotherapy treatment in malignant pheochromocytomas\/paragangliomas: a case report","volume":"15","author":"Rodriguez","year":"2021","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.labinv.2023.100210_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.labinv.2023.100210_bib34","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.labinv.2023.100210_bib35","first-page":"4234","article-title":"CD4(+) T cell exhaustion leads to adoptive transfer therapy failure which can be prevented by immune checkpoint blockade","volume":"10","author":"Fu","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.labinv.2023.100210_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/bfgp\/ely006","article-title":"CD8(+) T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy","volume":"18","author":"He","year":"2019","journal-title":"Brief Funct Genom"},{"key":"10.1016\/j.labinv.2023.100210_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.labinv.2023.100210_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","article-title":"Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.labinv.2023.100210_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.587779","article-title":"Histopathological analysis of tumor microenvironment and angiogenesis in pheochromocytoma","volume":"11","author":"Gao","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.labinv.2023.100210_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","article-title":"Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis","volume":"79","author":"Ghosal","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.labinv.2023.100210_bib41","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1038\/s41467-022-34011-3","article-title":"Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment","volume":"13","author":"Zethoven","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.labinv.2023.100210_bib42","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.labinv.2023.100210_bib43","article-title":"PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma","volume":"12","author":"Vanova","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.labinv.2023.100210_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1022131","article-title":"Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma","volume":"13","author":"Jin","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.labinv.2023.100210_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40618-020-01275-9","article-title":"Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature","volume":"43","author":"Guadagno","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.labinv.2023.100210_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","author":"Eisenhofer","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.labinv.2023.100210_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.labinv.2023.100210_bib48","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/cancers11081121","article-title":"Intricacies of the molecular machinery of catecholamine biosynthesis and secretion by chromaffin cells of the normal adrenal medulla and in pheochromocytoma and paraganglioma","volume":"11","author":"Berends","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.labinv.2023.100210_bib49","first-page":"589","article-title":"The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas","volume":"29","author":"Tufton","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.labinv.2023.100210_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/path.6026","article-title":"Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype","volume":"259","author":"Lucia","year":"2023","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.labinv.2023.100210_bib51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/onc.2016.225","article-title":"Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer","volume":"36","author":"Chouaib","year":"2017","journal-title":"Oncogene"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683723001538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683723001538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:58:57Z","timestamp":1758398337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683723001538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0023683723001538"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2023.100210","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma\/Paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2023.100210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100210"}}